Temsirolimus Plus Bortezomib Safe, Active for Relapsed/Refractory B-Cell NHL
the ONA take:
The combination of a mammalian target of rapamycin inhibitor and a proteasome inhibitor is safe and has activity in heavily pretreated patients with B-cell non-Hodgkin lymphoma, a recent study published in the journal Cancer has shown.
For the single-arm, phase 2 trial, researchers enrolled 39 patients with relapsed and refractory B-cell non-Hodgkin lymphoma.
The patients received bortezomib and temsirolimus weekly on days 1, 8, 15, and 22 of a 35-day cycle. This dosing scheme has previously been studied in patients with multiple myeloma.
Results showed that 7.7% of patients achieved a complete response and 23% achieved a partial response. Median progression-free survival was 4.7 months (2 months for patients with diffuse large B-cell lymphoma, 7.5 months for those with mantle cell lymphoma, and 16.5 months for those with follicular lymphoma).
Researchers found that two extensively treated patients with diffuse large B-cell lymphoma achieved a complete response. In regard to safety, there were no unexpected toxicities with the combination.
“Further studies with this combination are warranted in specific subtypes of NHL,” the authors conclude.
The combination of a mammalian target of rapamycin inhibitor and a proteasome inhibitor is safe in B-cell non-Hodgkin lymphoma.
- Physical Activity Improves Outcomes for Patients with Breast Cancer and Survivors
- Behavior Pain Assessment Tool Measures Pain In Patients Who Cannot Communicate Verbally
- Whole Genome Sequencing Reveals that 12% of Childhood Cancer Survivors Have Mutations in Genes that Increase Cancer Risk
- Increased 5-Year Survival Rate Seen in NSCLC Subset Treated With Nivolumab
- Novel Test For Multiple Myeloma Uses Microchip, Conventional Blood Sample
- Exercise, Psychological Interventions Better for Cancer Fatigue Than Medications
- ASCO Issues Global Guidance for HPV Vaccination for Cervical Cancer Prevention
- Discharge Events Improved With Standardized Inpatient Palliative Care Consultation
- Little Opposition to Early Palliative Care for Symptom Management in Pediatric Oncology
- Updated ASTRO Guideline Bolsters Safety, Efficacy of Palliative RT for Bone Metastases
- Thyroid Cancer Incidence Increasing Among Younger, Hispanic, African American Populations
- JAK1, JAK2 Inhibition Improves Outcomes in Myeloproliferative Neoplasms, But More Is Needed
- Recommendations Against Contralateral Prophylactic Mastectomy Not Tied to Patient Satisfaction
- Self-efficacy Level Predictive of Likelihood to Follow Through With Colorectal Cancer Screening
- Chronic Myeloproliferative Neoplasms Treatment (Fact Sheet)
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|